Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
P/E ratio for Advaxis, Inc. (ADXS)
P/E ratio as of 2023: -0.08
According to Advaxis, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.08. At the end of 2022 the company had a P/E ratio of -0.24.
P/E ratio history for Advaxis, Inc. from 2002 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.08 |
| 2022 | -0.24 |
| 2021 | -3.66 |
| 2020 | -0.78 |
| 2019 | -0.27 |
| 2018 | -35.11 |
| 2017 | -119.17 |
| 2016 | -314.62 |
| 2015 | -534.03 |
| 2014 | -266.00 |
| 2013 | -75.77 |
| 2012 | -96.58 |
| 2011 | -312.94 |
| 2010 | -174.81 |
| 2009 | 1305.72 |
| 2008 | -33.39 |
| 2007 | -330.44 |
| 2006 | -98.26 |
| 2005 | -408.32 |
| 2004 | -7562.29 |
| 2003 | -992985370.65 |
| 2002 | -992985370.65 |